A $30 test that could prevent a pointless $100K course of some oncology drug should capture more of the value it saves the system.
An excellent point, but I see the drug maker annointing the technology that combines with their drug since they have to run both through FDA approval trials. I'm not sure they'd want to put that much of the drug cost into a device made by another company.
On the other hand, pricing it that high would get the drug maker something even on patients they couldn't treat (assuming they got a piece of the device selling price). That's been the big drawback to personalized medicine from the drugmaker standpoint. Why give up XX% of the market when we can just overpower our trials to make up the difference.
MYGN has taken this to the next level and its stock price has done well recently as its testing diagnostics business grows very well. Somewhat controversial charging what it does for some of the breast cancer screening tests which may or may not work that well (something like $4K a pop). This business for them is probably worth the current stock price, making one wonder about other companies' AD valuations.
Market Data 
Markets 
AI
